RAND Corporation, Santa Monica, CA, USA.
RAND Corporation, Arlington, VA, USA.
Addiction. 2021 Jan;116(1):6-17. doi: 10.1111/add.15163. Epub 2020 Jul 8.
Naloxone access laws (NALs) have been suggested to be an important strategy to reduce opioid-related harm. We describe the evolution of NALs across states and over time and review existing evidence of their overall association with naloxone distribution and opioid overdose as well as the potential effects of specific NAL components.
Descriptive analysis of temporal variation in US regional adoption of NAL components, accompanied by a systematic search of 13 databases for studies (published between 2005 and 20 December 2019) assessing the effects of NALs on naloxone distribution or opioid-related health outcomes. Eleven studies, all published since 2018, met inclusion criteria. Study time-frames spanned 1999-2017. Opioid-related overdose mortality, emergency department episodes and naloxone distribution were correlated with the presence of a NAL and, where data were available, NAL components.
Existing evidence suggests mixed, but generally beneficial, effects for NALs. Nearly all studies show that NALs, particularly those that permit naloxone distribution without patient-specific prescriptions, are associated with increased naloxone access [incidence rate ratios (IRR) range from 1.40, 95% confidence interval (CI) = 1.15-1.66 to 7.75, 95% CI = 1.22-49.35] and increased opioid-related emergency department visits (IRR range from 1.14, 95% CI = 1.07-1.20 to 1.15, 95% CI = 1.02-1.29). Most studies show NALs are associated with reduced overdose mortality, although findings vary depending on the specific NAL components and time-period analyzed (IRR range from 0.66, 95% CI = 0.42-0.90 to 1.27, 95% CI = 1.27-1.27). Few studies account for the variation in opioid environments (i.e. illicit versus prescription) or other policy dimensions that may be correlated with outcomes.
The existing literature on naloxone access laws in the United States supports beneficial effects for increased naloxone distribution, but provides inconclusive evidence for reduced fatal opioid overdose. Mixed findings may reflect variation in the laws' design and implementation, confounding effects of concurrent policy adoption, or differential effectiveness in light of changing opioid environments.
纳洛酮获取法(NAL)被认为是减少阿片类药物相关伤害的重要策略。我们描述了各州和随着时间的推移 NAL 的演变,并审查了现有证据,证明它们与纳洛酮的分发和阿片类药物过量之间存在总体关联,以及特定 NAL 成分的潜在影响。
对美国地区采用 NAL 成分的时间变化进行描述性分析,同时系统搜索了 13 个数据库,以评估 NAL 对纳洛酮分布或阿片类相关健康结果的影响。11 项研究符合纳入标准,均发表于 2018 年之后。研究时间范围为 1999-2017 年。阿片类相关过量死亡、急诊发作和纳洛酮分发与 NAL 的存在相关,在有数据的情况下,还与 NAL 成分相关。
现有证据表明,NAL 的影响喜忧参半,但总体上是有益的。几乎所有研究都表明,NAL 特别是那些允许在没有患者特定处方的情况下分发纳洛酮的 NAL,与增加纳洛酮的获取有关[发病率比(IRR)范围为 1.40,95%置信区间(CI)=1.15-1.66 至 7.75,95% CI=1.22-49.35]和增加与阿片类药物相关的急诊就诊(IRR 范围为 1.14,95% CI=1.07-1.20 至 1.15,95% CI=1.02-1.29)。大多数研究表明,NAL 与减少过量死亡率有关,但具体发现因特定的 NAL 成分和分析的时间周期而异(IRR 范围为 0.66,95% CI=0.42-0.90 至 1.27,95% CI=1.27-1.27)。很少有研究考虑到阿片类药物环境(即非法与处方)或可能与结果相关的其他政策维度的变化。
美国关于纳洛酮获取法的现有文献支持增加纳洛酮分发的有益效果,但提供的减少致命阿片类药物过量的证据并不确定。混合的结果可能反映了法律设计和实施的变化、同期政策采用的混淆效应,或根据不断变化的阿片类药物环境的不同效果。